What is the recommended evaluation and management for ocular (retinal) migraine, including acute treatment and prophylaxis?

Ocular (Retinal) Migraine: Evaluation and Management

Immediate Diagnostic Priority

Retinal migraine is a diagnosis of exclusion requiring urgent evaluation to rule out serious causes of monocular vision loss before attributing symptoms to migraine. 1, 2

Critical Red Flags Requiring Urgent Investigation

Any patient presenting with monocular vision loss must be thoroughly investigated for secondary causes before diagnosing retinal migraine 1:

• Thunderclap headache suggests subarachnoid hemorrhage 3
• Atypical aura patterns may indicate transient ischemic attack, stroke, epilepsy, or arteriovenous malformations 3
• Focal neurological symptoms beyond typical visual phenomena 3
• New onset after age 50 warrants consideration of temporal arteritis and other secondary headaches 3
• Progressive symptoms or incomplete resolution should prompt immediate vascular imaging 4

Essential Workup Components

Complete cerebrovascular evaluation is mandatory 4:

• Fundoscopic examination during attack (if possible) may reveal retinal vasoconstriction 1
• Optical coherence tomography angiography (OCTA) can document reduced retinal perfusion during attacks 5
• Vascular imaging (carotid ultrasound, MRA, or CTA) to exclude embolic sources, dissection, or vasculitis 4, 6
• Cardiac evaluation including echocardiography if embolic source suspected 6
• Hypercoagulability workup in appropriate clinical contexts 6

Clinical Characteristics

Retinal migraine typically affects women in their second to third decade of life 6, 7:

• Monocular visual loss (partial or complete) lasting less than 1 hour 1, 7
• Headache is typically ipsilateral to the affected eye 1
• Most patients have prior history of migraine with aura, contrary to ICHD-2 criteria 6
• Visual symptoms include scintillations, scotomas, or complete blindness 2

Critical Prognostic Warning

Nearly half of patients with recurrent retinal migraine attacks subsequently develop permanent monocular visual loss, representing migrainous infarction of the retina or optic nerve 6, 7. This risk of irreversible vision loss fundamentally changes the management approach.

Acute Treatment

Use standard migraine abortive therapies immediately at symptom onset 1, 4:

• NSAIDs (aspirin, ibuprofen, or diclofenac potassium) as first-line acute treatment 3
• Triptans as second-line therapy 3
• Gepants or ditans as third-line options 3
• Prokinetic antiemetics (domperidone or metoclopramide) for associated nausea 3, 8

Medications to Strictly Avoid

Never use opioids, barbiturates, or oral ergot alkaloids for retinal migraine 3, 8:

• Opioids and barbiturates have questionable efficacy and risk dependence 3, 8
• Ergot alkaloids are poorly effective and potentially toxic 3, 8
• All three classes increase risk of medication-overuse headache 8

Prophylactic Treatment: The Critical Recommendation

Given the substantial risk of permanent vision loss (approaching 50%), prophylactic therapy should be initiated even with infrequent attacks 6. This represents a departure from typical migraine management where prophylaxis is reserved for frequent attacks.

First-Line Preventive Agents

Start with beta-blockers (propranolol or metoprolol), topiramate, or candesartan 8:

• These medications reduce recurrence risk and may prevent migrainous infarction 8
• Angiotensin-receptor blockers (candesartan) and lisinopril are supported by VA/DoD guidelines 3
• Topiramate and valproate have strong evidence for episodic migraine prevention 3

Second-Line Options

If first-line agents are unsuitable or ineffective 8:

• Flunarizine (where available)
• Amitriptyline for chronic prevention

Third-Line Therapy

CGRP monoclonal antibodies (eptinezumab, atogepant) for refractory cases 3, 8:

• Eptinezumab and atogepant have evidence for episodic migraine prevention 3
• Assess efficacy only after 3-6 months of treatment 3

Prophylaxis Duration and Monitoring

• Continue oral preventives for 2-3 months before assessing efficacy 3
• Do not abandon treatment prematurely; efficacy takes weeks to months 3
• Long-term prophylaxis is justified given the risk of permanent visual loss 6

Medication-Overuse Prevention

Educate patients that acute medication use exceeding 10 days/month for triptans or 15 days/month for simple analgesics markedly increases risk of medication-overuse headache 8:

• This can lead to progression to chronic migraine 8
• Emphasize early use of effective acute treatment rather than frequent dosing 3

Special Considerations

Pathophysiology Insight

The mechanism likely involves vasoconstriction of retinal vessels, as documented by ictal fundus photography and OCTA showing reduced retinal perfusion during attacks 1, 5:

• Parafoveal vessel flux index decreases by 7% during attacks in both migraine with and without aura 5
• This differs from typical migraine aura mechanisms, making "retinal migraine" potentially a misnomer 2

Adjunctive Non-Pharmacologic Measures

Aerobic exercise or physical therapy can be incorporated into overall migraine management 3, though specific evidence for retinal migraine is limited.

Optical interventions targeting intrinsically photosensitive retinal ganglion cells may reduce light sensitivity and pain 9, though this requires further validation.